Cargando…
SARS-CoV-2 vaccines: Lights and shadows
Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit an immune neutralizing response. Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on case-reports of serious thromboembolic events after vaccination. Some mechanisms ha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084611/ https://www.ncbi.nlm.nih.gov/pubmed/33966930 http://dx.doi.org/10.1016/j.ejim.2021.04.019 |
_version_ | 1783686188356337664 |
---|---|
author | Angeli, Fabio Spanevello, Antonio Reboldi, Gianpaolo Visca, Dina Verdecchia, Paolo |
author_facet | Angeli, Fabio Spanevello, Antonio Reboldi, Gianpaolo Visca, Dina Verdecchia, Paolo |
author_sort | Angeli, Fabio |
collection | PubMed |
description | Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit an immune neutralizing response. Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on case-reports of serious thromboembolic events after vaccination. Some mechanisms have been suggested which might explain the adverse cardiovascular reactions to SARS-CoV-2 vaccines. Different vaccine platforms are currently available which include live attenuated vaccines, inactivated vaccines, recombinant protein vaccines, vector vaccines, DNA vaccines and RNA vaccines. Vaccines increase the endogenous synthesis of SARS-CoV-2 Spike proteins from a variety of cells. Once synthetized, the Spike proteins assembled in the cytoplasma migrate to the cell surface and protrude with a native-like conformation. These proteins are recognized by the immune system which rapidly develops an immune response. Such response appears to be quite vigorous in the presence of DNA vaccines which encode viral vectors, as well as in subjects who are immunized because of previous exposure to SARS-CoV-2. The resulting pathological features may resemble those of active coronavirus disease. The free-floating Spike proteins synthetized by cells targeted by vaccine and destroyed by the immune response circulate in the blood and systematically interact with angiotensin converting enzyme 2 (ACE2) receptors expressed by a variety of cells including platelets, thereby promoting ACE2 internalization and degradation. These reactions may ultimately lead to platelet aggregation, thrombosis and inflammation mediated by several mechanisms including platelet ACE2 receptors. Whereas Phase III vaccine trials generally excluded participants with previous immunization, vaccination of huge populations in the real life will inevitably include individuals with preexisting immunity. This might lead to excessively enhanced inflammatory and thrombotic reactions in occasional subjects. Further research is urgently needed in this area. |
format | Online Article Text |
id | pubmed-8084611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Federation of Internal Medicine. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80846112021-05-03 SARS-CoV-2 vaccines: Lights and shadows Angeli, Fabio Spanevello, Antonio Reboldi, Gianpaolo Visca, Dina Verdecchia, Paolo Eur J Intern Med Review Article Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit an immune neutralizing response. Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on case-reports of serious thromboembolic events after vaccination. Some mechanisms have been suggested which might explain the adverse cardiovascular reactions to SARS-CoV-2 vaccines. Different vaccine platforms are currently available which include live attenuated vaccines, inactivated vaccines, recombinant protein vaccines, vector vaccines, DNA vaccines and RNA vaccines. Vaccines increase the endogenous synthesis of SARS-CoV-2 Spike proteins from a variety of cells. Once synthetized, the Spike proteins assembled in the cytoplasma migrate to the cell surface and protrude with a native-like conformation. These proteins are recognized by the immune system which rapidly develops an immune response. Such response appears to be quite vigorous in the presence of DNA vaccines which encode viral vectors, as well as in subjects who are immunized because of previous exposure to SARS-CoV-2. The resulting pathological features may resemble those of active coronavirus disease. The free-floating Spike proteins synthetized by cells targeted by vaccine and destroyed by the immune response circulate in the blood and systematically interact with angiotensin converting enzyme 2 (ACE2) receptors expressed by a variety of cells including platelets, thereby promoting ACE2 internalization and degradation. These reactions may ultimately lead to platelet aggregation, thrombosis and inflammation mediated by several mechanisms including platelet ACE2 receptors. Whereas Phase III vaccine trials generally excluded participants with previous immunization, vaccination of huge populations in the real life will inevitably include individuals with preexisting immunity. This might lead to excessively enhanced inflammatory and thrombotic reactions in occasional subjects. Further research is urgently needed in this area. European Federation of Internal Medicine. Published by Elsevier B.V. 2021-06 2021-04-30 /pmc/articles/PMC8084611/ /pubmed/33966930 http://dx.doi.org/10.1016/j.ejim.2021.04.019 Text en © 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Angeli, Fabio Spanevello, Antonio Reboldi, Gianpaolo Visca, Dina Verdecchia, Paolo SARS-CoV-2 vaccines: Lights and shadows |
title | SARS-CoV-2 vaccines: Lights and shadows |
title_full | SARS-CoV-2 vaccines: Lights and shadows |
title_fullStr | SARS-CoV-2 vaccines: Lights and shadows |
title_full_unstemmed | SARS-CoV-2 vaccines: Lights and shadows |
title_short | SARS-CoV-2 vaccines: Lights and shadows |
title_sort | sars-cov-2 vaccines: lights and shadows |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084611/ https://www.ncbi.nlm.nih.gov/pubmed/33966930 http://dx.doi.org/10.1016/j.ejim.2021.04.019 |
work_keys_str_mv | AT angelifabio sarscov2vaccineslightsandshadows AT spanevelloantonio sarscov2vaccineslightsandshadows AT reboldigianpaolo sarscov2vaccineslightsandshadows AT viscadina sarscov2vaccineslightsandshadows AT verdecchiapaolo sarscov2vaccineslightsandshadows |